NUVL
Nuvalent, Inc.
NASDAQ · Healthcare · Biotechnology · US
$123.96
+0.00%Jul 28, 2026, 18:30 UTC
GSK completes the acquisition of US-based cancer specialist Nuvalent for nearly £8 billion.
Source:Jul 22, 2026, 17:58 UTC
The US FDA approved GSK's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.
Jun 24, 2026, 19:36 UTC
Nuvalent, Inc. agreed to be acquired by GSK plc for $124.00 per share in cash.